Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 16, 2007

Pfizer Attains Rights to Genizon BioSciences Discovery Programs

  • Genizon BioSciences reported a license and collaboration agreement with Pfizer for diagnostic rights to Genizon’s discovery programs in Alzheimer’s disease, attention deficit hyperactivity disorder, and endometriosis. Genizon retains therapeutic rights.

    Under the terms of the agreement, Pfizer will pay Genizon upfront license fees and funding for research on genetic variations associated with the diseases. Pfizer will also purchase an equity stake in Genizon.

    The collaboration involves discovery of diagnostic markers from three ongoing genome-wide association studies of the Quebec Founder Population using Genizon’s technology platform. The unique genetic heritage of the Quebec Founder Population facilitates discovery of genetic markers that are predictive of disease susceptibility, according to the company.
    The collaboration will expand these discoveries by including results with those from genome wide association studies from general populations.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »